Intellia Therapeutics Inc. (NTLA)
NTLA trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/0001193125-26-076550-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NTLA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001652130 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $67.7M |
| Net income | -$412.7M |
| Operating income | -$441.0M |
| Net margin | -609.9% |
| Operating margin | -651.7% |
| Revenue growth | +16.9% |
| Cash | $155.5M |
| Total assets | $842.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 20.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $156.1M cash; operating cash flow -$88.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 140,358,512 (2026-10-30); 115,829,926 a year earlier; 89,554,891 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-04-29 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.4M, sold $2.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $7.2M | -$127.5M | -$85.4M | $156.1M | $73.7M | $52.9M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $7.7M | -$106.6M | -$83.1M | $106.1M | No debt tags | $59.5M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $15.0M | -$96.2M | -$117.3M | $134.7M | No debt tags | $66.1M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $23.0M | -$95.8M | -$69.3M | $155.5M | $0 | $67.7M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $13.8M | -$101.3M | -$76.9M | $193.4M | No debt tags | $57.5M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $14.2M | -$101.3M | -$99.6M | $156.2M | No debt tags | $52.9M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $16.6M | -$114.3M | -$148.9M | $126.9M | No debt tags | $45.6M | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $12.9M | -$128.9M | -$85.2M | $189.2M | No debt tags | $57.9M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-29 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K/A | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 726 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -14.5% |
| 1 month | -18.6% |
| 3 months | -18.0% |
| Year to date | +7.9% |
| 1 year | +11.9% |
| From 52-week high | -45.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CLDX | Celldex Therapeutics Inc. | $28.59 | -0.83% | $2.2B |
| NEOG | Neogen Corporation | $10.88 | -3.12% | $2.4B |
| QDEL | QuidelOrtho Corporation | $10.21 | -4.93% | $700.5M |
| QUIT | Achieve Life Sciences Inc. Common Shares | $6.06 | -4.11% | $666.8M |
| NNNN | Anbio Biotechnology | $3.88 | +1.57% | $558.3M |
| MYGN | Myriad Genetics Inc. | $5.57 | -1.59% | $534.3M |
| TKNO | Alpha Teknova Inc. | $7.77 | -5.36% | $488.8M |
| LNTH | Lantheus Holdings Inc. | $101.72 | +0.13% | $6.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier